Close Menu

This article has been updated with additional information from Memorial Sloan Kettering Cancer Center.

NEW YORK (GenomeWeb) – The US Food and Drug Administration said today that it has authorized Memorial Sloan Kettering Cancer Center's MSK-IMPACT next-generation sequencing tumor profiling assay as an in vitro diagnostic test. In addition, the agency said that it has accredited the New York State Department of Health (NYSDOH) as an FDA third-party reviewer of IVDs, including similar tumor profiling tests.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.